EGFR and cancer: Furthermore, the altered miRNome influenced various cancer pathways, including the proliferation, metastasis, cell cycle, apoptosis, mammalian target of rapamycin (mTOR), focal adhesion, p53, carbohydrate digestion and absorption, insulin, cell cycle, Janus kinase (JAK)-signal transducer and activator of transcription (STAT), ErbB, adherens, neurotrophin, T cell receptor, and endocytosis pathways.